Tag: Repatha

In January 2023, a reanalysis published in the journal *BMJ Open* reignited debate over the cardiovascular outcomes data of Repatha (evolocumab). This study, based on a review of the original clinical report, highlights significant inconsistencies, adding another layer to the long-standing question of **what is the controversy with Repatha**.

Globally, high cholesterol is responsible for an estimated 4.4 million deaths each year. For patients needing significant reduction of LDL cholesterol, understanding treatment options is critical. So, **how is Evolocumab administered** to manage this risk?

In January 2017, a U.S. judge ordered Praluent off the market within 30 days, citing patent infringement, a decision that created significant uncertainty for patients and healthcare providers. However, this ban never took permanent effect in the United States, raising questions about the drug's true market status and **why was Praluent pulled from the market** in some regions more recently. The situation involves complex legal battles, evolving market strategies, and global supply chain challenges.

According to clinical trial data, injection site reactions were experienced by a small percentage of patients, emphasizing the importance of proper injection technique for comfort and effectiveness. Here is a comprehensive guide on **how to inj repatha** safely and confidently at home.

As of mid-2025, pharmaceutical manufacturer Amgen is phasing out certain delivery systems for its cholesterol-lowering medication, Repatha, leaving many patients to wonder: **Why are they discontinuing Repatha?** This decision specifically affects the Pushtronex System and standard prefilled syringes, but it is not due to any safety or efficacy issues with the drug itself.